- Trial phase
- Phase 2
- Time to market
- SPY001 is in Phase 2 trials. If Part B data is positive and the company proceeds to Phase 3, potential FDA approval is likely several years away, likely not before 2029-2030 at the earliest.
- Why 4/10
- SPY001 is a Phase 2 asset whose next hard, dated catalyst is the SKYLINE Part B induction readout expected in 2027, more than 12 months from today. The drug is a major pipeline driver for Spyre, but the company also has multiple other programs (SPY002, SPY003, SPY072) and over $1.5B in cash, so it is not a single-asset binary. Per the rubric, a mid-stage drug with no catalyst within ~12 months scores 3-5; the default of 4 applies.
The next major catalyst for SPY001 is the SKYLINE Part B induction data readout expected in 2027, which will test both monotherapy and combination regimens. Positive data could validate the combination strategy and strengthen the best-in-class thesis against Entyvio, while negative or mixed results would raise questions about the platform approach. In the interim, watch for any SKYLINE Part B enrollment updates, preclinical data presentations at medical conferences, and potential partnership or licensing announcements given the company's strong cash position.
Price Chart
Executive Summary
SPY001 is Spyre Therapeutics' long-acting anti-alpha4beta7 antibody for ulcerative colitis, designed to compete with Takeda's blockbuster Entyvio. Phase 2 Part A induction data from April 2026 showed strong efficacy (9.2-point RHI reduction, 40% clinical remission) with a clean safety profile, positioning it as a potential best-in-class therapy. The company has completed proof-of-concept for all three monotherapies in its IBD pipeline. The next major catalyst is the SKYLINE Part B induction readout in 2027, which will test both monotherapy and combination regimens. Spyre has a strong cash position ($1.5B pro forma, runway into H2 2029) and broad institutional support, but the stock faces near-term headwinds from elevated short volume, insider selling under 10b5-1 plans, and a Q3 2026 earnings miss.
How It Works
SPY001 is a long-acting monoclonal antibody that blocks the alpha4beta7 integrin, a protein on the surface of certain immune cells. By blocking this protein, the drug prevents those immune cells from entering the gut lining, reducing the inflammation that drives ulcerative colitis and other inflammatory bowel diseases. It targets the same biological pathway as Takeda's blockbuster drug Entyvio (vedolizumab) but is engineered with a longer half-life, potentially allowing patients to receive injections every three to six months instead of monthly infusions.
Trial Status
SPY001 is being evaluated in the Phase 2 SKYLINE platform trial for moderate-to-severely active ulcerative colitis. Part A (induction monotherapy) completed enrollment and reported positive 12-week topline data on April 13, 2026. The drug met its primary endpoint with a statistically significant 9.2-point reduction in the Robarts Histopathology Index (p<0.0001). Key secondary endpoints showed a 40% clinical remission rate and 51% endoscopic improvement at week 12, among the highest rates reported in comparable UC trials. Safety was consistent with the alpha4beta7 class. Part B of SKYLINE is currently enrolling patients across three monotherapy cohorts (SPY001, SPY002, SPY003) and three combination cohorts (SPY120, SPY130, SPY230), with induction readout expected in 2027.
The Two-Sided Case
Upcoming Catalysts
- SKYLINE Part B induction data readout for SPY001 monotherapy and combination cohorts (SPY120, SPY130, SPY230) expected in 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report